Sepsis is a life-threatening health condition that is initially characterized by uncontrolled inflammation, followed by the development of persistent immunosuppression. YCP is a novel α-glucan purified from the mycelium of the marine fungus Phoma herbarum YS4108, which has displayed strong antitumor activity via enhancing host immune responses. In this study, we investigated whether YCP could influence the development of sepsis in a mouse model. Caecal ligation and puncture (CLP)-induced sepsis was established in mice that were treated with YCP (20 mg/kg, ip or iv) 2 h before, 4 and 24 h after the CLP procedure, and then every other day. YCP administration greatly improved the survival rate (from 39% to 72% on d 10 post-CLP) and ameliorated disease symptoms in the septic mice. Furthermore, YCP administration significantly decreased the percentage of myeloid-derived suppressor cells (MDSCs) in the lungs and livers, which were dramatically elevated during sepsis. In cultured BM-derived cells, addition of YCP (30, 100 μg/mL) significantly decreased the expansion of MDSCs; YCP dose-dependently decreased the phosphorylation of STAT3 and increased the expression of interferon regulatory factor-8 (IRF-8). When BM-derived MDSCs were co-cultured with T cells, YCP dose-dependently increased the production of arginase-1 (Arg-1) and inducible nitric oxide synthase (iNOS), and activated the NF-κB pathway. In addition, the effects of YCP on MDSCs appeared to be dependent on toll-like receptor (TLR) 4. These results reveal that YCP inhibits the expansion of MDSCs via STAT3 while enhancing their immunosuppressive function, partially through NF-κB. Our findings suggest that YCP protects mice against sepsis by regulating MDSCs. Thus, YCP may be a potential therapeutic agent for sepsis.
Sepsis is defined as a host inflammatory response to a life-threatening infection with the presence of some degree of organ dysfunction1,2. It is an increasingly common and lethal medical condition that occurs in people of all ages. It is the leading cause of mortality in intensive care units (ICUs) worldwide3,4,5. Therefore, new drug development and more effective therapies targeting sepsis are in high demand. Recent studies have demonstrated that both overwhelming pro-inflammatory and anti-inflammatory responses occur rapidly and simultaneously during sepsis. Although unrestrained inflammation is dominant in the early phase3,6,7,8, this initial hyper-inflammatory response evolves into a prolonged immunosuppressive stage several days later9,10. Several studies have suggested that sepsis-associated immunosuppression increases mortality; hence, therapies that balance pro- and anti-inflammatory pathways may be effective strategies for improving the survival rate of septic patients3,9.
Various natural polysaccharides possess the ability to activate the immune system. It has been reported that β-glucan and α-glucan protect against both infections11,12,13,14 and malignancies12. We have previously identified a novel α-glucan with a molecular weight of 2.4×103 kDa, which we purified from the mycelium of the marine fungus Phoma herbarum YS4108, named YCP. YCP exhibits strong antitumor activity by enhancing the host's immunity15,16,17,18. YCP treatment induces nitric oxide (NO) production in macrophages16, promotes the proliferation of murine splenic B cells17,18, provides a second signal for T cells and effectively stimulates dendritic cells (DCs) to secrete interleukin (IL)-12 and express surface activation markers15. Moreover, we have found that toll-like receptor (TLR) 4 may be responsible for the functions of YCP15,16,17,18. However, it remains unclear whether YCP can influence the development of sepsis.
Sepsis deeply perturbs immune homeostasis8 and directly or indirectly affects almost all types of immune cells3. Recent studies have shown that the development of sepsis is related to the expansion of myeloid-derived suppressor cells (MDSCs)19,20,21,22,23. MDSCs, which are a heterogeneous population of immature myeloid cells composed of following two subsets, monocytic MDSCs (M-MDSCs) and granulocytic MDSCs (G-MDSCs), are a major component of the immunosuppressive network in many pathological conditions, including sepsis24,25,26. MDSCs are dramatically increased in lung tissues27 and blood samples22,28 obtained from sepsis patients. Moreover, in the cecal ligation and puncture (CLP)-induced model of sepsis in mice, the number of MDSCs gradually increases and remains dramatically elevated in the bone marrow (BM), spleen, blood, and lymph nodes19,21,29,30. Notably, MDSCs may evolve during the development of sepsis21,29,31. It has been found that the adoptive transfer of MDSCs harvested at the late stage of sepsis into naive mice immediately after CLP surgery decreases pro-inflammatory cytokine production, increases peritoneal bacterial growth, and improves survival rate21,29. In addition, in vitro experiments have shown that these MDSCs are highly responsive to lipopolysaccharide (LPS) in terms of cytokine secretion, NF-kB activation, reactive oxygen species (ROS) production and arginase I (Arg-1) activity21. Conversely, MDSCs obtained from early stage sepsis promote the opposite effects21,29. These observations strongly suggest that the heterogeneous MDSCs might shift their state as the sepsis inflammatory process progresses29. Furthermore, recent findings have also suggested that MDSCs may be amenable targets for host-directed therapies26,32. Hence, a better understanding of MDSC generation and/or regulation may provide novel insights for the treatment of sepsis.
In the present study, we aimed to investigate the potentially protective effect of the α-glucan YCP against CLP-induced sepsis in mice and the possible underlying mechanisms. Our results showed that YCP significantly improved the survival rates of the septic mice and resulted in a decreased percentage of MDSCs. Therefore, we further explored how YCP regulates MDSCs. Our findings provide evidence for the potential use of YCP in the treatment of sepsis.
Materials and methods
YCP is a natural α-glucan with a molecular weight (MW) of 2.4×103 kDa. YCP was purified from the mycelium of the marine filamentous fungus Phoma herbarum YS4108, which inhabits the sediment in the Yellow Sea area near Yancheng, China. YCP has a backbone of α-1,4-D-glucans with a lower proportion of α-1,6-linked glucopyranosyl and glucuronic acid residues as non-reducing termini. YCP was purified by a combination of ion-exchange chromatography on DEAE-32 and gel permeation over Sephacryl S-40033. The purity of YCP was shown as a single chromatographic peak on an Agilent 1100 HPLC system equipped with a gel permeation chromatographic column Shodex KS-805. The endotoxin contamination in YCP was also proven to be negligible by an LAL chromogenic endpoint assay17.
C57BL/6J male mice (8–12 weeks old, 25–30 g) were purchased from the Animal Model Research Institute of Nanjing University (Nanjing, China). The mice were then housed in a pathogen-free barrier facility under a 12 h light/dark cycle. The experimental methods described here were carried out in accordance with the guidelines of the Experimental Animal Management Committee (Jiangsu Province, China). All procedures were approved by the Committee on the Ethics of Animal Experiments at Nanjing University (SYXK 2014-0052).
BM-derived MDSCs were obtained as previously described34. In brief, BM cells were flushed from the femurs and tibias of approximately 10-week-old C57BL/6J mice. The red blood cells (RBCs) were lysed with an ACK lysis buffer containing 0.15 mol/L NH4Cl, 10 mmol/L KHCO3, and 0.1 mmol/L Na2EDTA. The BM cells were then cultured in an RPMI-1640 medium supplemented with 10% FBS (Gibco/Invitrogen Corporation, CA, USA), 100 U/mL penicillin and 100 U/mL streptomycin and stimulated with 40 ng/mL IL-6 (PeproTech, Rocky Hill, NJ, USA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Miltenyi Biotec, Bergisch Gladbach, Germany) at 37 °C in a 5% CO2-humidified atmosphere for 4 d. For the MDSC expansion experiments, the culture medium was additionally supplemented with varying concentrations of YCP.
Cecal ligation and puncture model of sepsis
CLP was performed as previously described35. In this study, we ligated the cecum halfway between the distal pole and the base and perforated the cecum with a single puncture midway between the ligation and the cecum tip. The control sham-operated mice were treated identically except for that the cecum was neither ligated nor punctured. CLP mice were randomly assigned to groups receiving injections of either YCP or sterile saline. In the YCP-treated group, mice received 20 mg/kg YCP dissolved in saline by intraperitoneal injections 2 h before, 4 h after and 24 h after the CLP procedure and every other day after that. In both the sham-operated and CLP groups, control mice received sterile saline. After the experiment, all mice were euthanized, and tissue samples were collected. To test the effect of YCP on the survival rate of the septic mice, YCP was administered both intraperitoneally and intravenously.
Blood and peritoneal bacterial culture
Blood and peritoneal lavage fluid were collected from the mice immediately after euthanasia and were then serially diluted with sterile saline. The blood was plated in 5% sheep blood agar plates, and the peritoneal lavage fluid was plated in agar plates. All plates were incubated for 18 h at 37 °C under aerobic conditions. CFUs were counted and multiplied by the dilution factor for the bacterial load quantification. The results are expressed as CFU counts per milliliter of blood or peritoneal lavage fluid.
The sera and bronchoalveolar lavage fluid (BALF) samples were collected 24 h after the CLP operation. To obtain the sera, blood was collected and centrifuged at 900×g for 10 min; after the coagulation at room temperature, the sera were separated and stored at -80 °C. To obtain BALF, 20 μL of 1× PBS per gram of mouse body weight was injected and retrieved following tracheostomy. The BALF was centrifuged at 900×g for 10 min at 4 °C, and the supernatants were stored at -80 °C until use in the cytokine expression analysis. The levels of IL-6 and tumor necrosis factor-α (TNFα) in serum and BALF were measured with enzyme-linked immunosorbent assays (ELISA) (BioLegend, San Diego, CA, USA).
Reverse transcription PCR and quantitative real-time PCR analysis
The total RNA of the BM-derived MDSCs was extracted with the TRIzol reagent (Invitrogen, San Diego, CA, USA) according to the manufacturer's instructions. Following the extraction, oligo(dT) primers were used to reverse-transcribe the mRNA into cDNA. Quantitative real-time PCR (q-PCR) assays were performed on a StepOne Plus or an ABI Vii 7 detection system (Applied Biosystems, Foster City, CA, USA) with SYBR Green PCR master mix solution. The relative gene expression was calculated with the 2-ΔCTformula; GAPDH was used as the internal control.
Flow cytometry analysis
To obtain single cell suspensions, the lung and liver tissues were cut into small pieces and digested in RPMI-1640 containing 3 mg/mL collagenase I or IV at 37 °C for 30 min on a shaker. The BM cells were flushed from the femurs and tibias. The spleens were mashed to obtain the splenocytes. The cells derived from each tissue sample were separately passed through a 200-mesh sieve. The RBCs were removed by ACK lysis. MDSCs were labeled with CD11b-APC and Gr1-PE. The M-MDSCs and G-MDSCs were uniquely detected by CD11b-FITC, Ly6G-APC (clone: 1A8), and Ly6C-PE. All antibodies and isotype-matched controls were purchased from BD PharmingenTM (San Diego, CA, USA). The appropriate isotype-matched control was used for each antibody. The BM cells, which were treated with YCP at concentrations of 0, 10, 30 or 100 μg/mL for 2 d, were stained with Annexin V and PI to detect apoptotic cells using the Annexin V-FITC & PI Apoptosis Kit (Biouniquer, San Diego, CA, USA). The BM-derived MDSCs were harvested and incubated with DCFH-DA (Beyotime, Shanghai, China) to measure the levels of ROS. Flow cytometry was performed on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The data were analyzed using FlowJo software (Treestar, Inc, San Carlos, CA, USA).
Western blotting was performed as described previously36. Anti-mouse p-STAT3 (Cell Signaling Technology (CST), Danvers, MA, USA), STAT3 (CST), anti-arginine (Bioworld, MN, USA), anti-p-p65 (CST), and anti-GAPDH (CST) were used as primary antibodies. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit or anti-mouse antibodies were used as secondary antibodies. The Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA) was used to detect the protein bands. Images were obtained using the MiniChemiTM Chemiluminescence imaging system (Sage Creation, Beijing, China).
Cell viability assays
The cytotoxicity of YCP on BM cells was measured by a Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) according to the manufacturer's protocol. The BM cells were treated with different concentrations of YCP in the presence of IL-6 and GM-CSF (40 ng/mL). Two or four days later, the cell viability was measured.
MDSC sorting and T cell proliferation
To obtain high-purity MDSCs, an MDSC isolation kit (Miltenyi Biotec) was used according to the manufacturer's instructions. For the T cell suppression assay, all splenic T cells were isolated from the C57BL/6J mice via negative selection using a mouse-Pan T cell isolation kit II (Miltenyi Biotec) and activated with anti-CD3 and anti-CD28 antibodies. The BM-derived MDSCs were treated with 50 μg/mL YCP or 1× PBS during their differentiation process in vitro. YCP was then removed, and high-purity G-MDSCs (Gr1highLy6G+) and M-MDSCs (Gr1dimLy6G-) were isolated. G-MDSCs were co-cultured at 1:1, 1:2, or 1:4 ratios with T cells, and M-MDSCs were co-cultured at 1:2 or 1:4 ratios with T cells in 96-well flat-bottom plates. T-cell proliferation was assessed by 3H]thymidine incorporation 72 h later.
Nitrite and arginase assays
BM-derived MDSCs cultured with 10 ng/mL IL-6 and GM-CSF were treated with YCP at concentrations of 0, 10, 30 or 100 μg/mL for 24 h. NO production was measured in the culture supernatants using the Griess reagent according to the manufacturer's protocol. To assess arginase activity, BM-derived MDSCs were harvested after the treatment with YCP for 36 h, and the activity was measured in the cell lysate with an arginase assay kit (BioAssay Systems, Hayward, CA, USA). In brief, approximately 1×106 cells were harvested and lysed in 100 μL of 10 mmol/L Tris-HCl (pH 7.4) containing 1 μmol/L pepstatin A, 1 μmol/L leupeptin, and 0.4% (w/v) Triton X-100 for 10 min. The lysates were centrifuged at 14 000×g for 10 min, and the supernatants were collected for the arginase activity assessment. All samples were diluted 5 times, and then, 40 μL of the diluted samples were mixed with 10 μL of the 5× substrate buffers in a 96-well plate, which was incubated at 37 °C for 2 h. The reaction was stopped by adding 200 μL of the supplied urea reagent to all wells. The plate was incubated for 60 min at room temperature, and the optical density was read at 430 nm. Arginase activity was calculated according to the formula provided by the manufacturer.
All data were analyzed with Prism 5 (GraphPad Software, Inc, San Diego, CA, USA) and expressed as the mean±SEM. Student's t-tests (two-tailed) were used to compare the differences between the various treatment groups. Statistical comparisons between the survival curves were performed using a log-rank (Mantel-Cox) test. Differences with P<0.05 were considered statistically significant. The in vitro experiments were repeated independently at least three times.
YCP improves survival and ameliorates disease symptoms in septic mice
To study the effect of YCP on CLP-induced polymicrobial sepsis, mice were treated with YCP several times before and after the CLP surgery. Intriguingly, we found that YCP significantly improved the survival rates of the septic mice regardless of whether it was administered through intraperitoneal or intravenous injections. After the study (10 d post-CLP), the survival rates had increased to 72% in the group treated with YCP intraperitoneally compared with only 39% in the control CLP group (Figure 1A). The intravenous administration of YCP also increased the survival rate from 36% to 71% (Figure 1A).
To elucidate the effects of YCP during sepsis, we evaluated the disease symptoms in septic mice with or without the YCP treatment. We found that the YCP treatment reduced the bacterial colony forming unit (CFU) counts in both the blood and peritoneal fluid (Figure 1B), which were collected 24 h after the CLP procedure. The YCP treatment also significantly reduced the levels of the inflammatory cytokines IL-6 and TNFα in the sera (Figure 1C) and the level of IL-6 in the bronchoalveolar lavage fluid (BALF) samples collected from the septic mice (Figure 1D). Additionally, the levels of the biochemical indicators of organ function were assessed in the sera. The aspartate aminotransferase (AST), alanine aminotransferase (ALT), and blood urea nitrogen (BUN) levels were all increased in the septic mice compared with those in the sham-operated mice, whereas the creatinine levels remained unchanged (Figure 1E). The YCP treatment decreased the systemic levels of AST and BUN but did not affect the levels of ALT and creatinine (Figure 1E). Furthermore, a histological assessment of lung, liver and kidney sections stained with hematoxylin and eosin also revealed multiple organ damage. The organ specimens from the CLP group displayed histological abnormalities and marked inflammatory infiltration. The specimens from the YCP-treated mice showed a substantial suppression of CLP-induced pathology in terms of both damage and inflammatory infiltration (Figure 1F). Altogether, these data demonstrate that the YCP treatment can effectively improve survival and ameliorate disease symptoms in septic mice.
YCP reduces the percentage of MDSCs in the lungs and livers of septic mice
Recent studies have demonstrated that the number of MDSCs dramatically increases and remains elevated in the BM, spleen, blood, and lymph nodes of CLP-induced septic mice19,21,29,30. In this study, our results showed that the percentage of CD11b+Gr1+ MDSCs was not only significantly increased in the BM and spleen but was also elevated in the damaged lungs and livers of the mice that underwent CLP (Figure 2A, 2B).
Interestingly, we found that the YCP treatment appeared to decrease the frequency of MDSCs in both the lung and liver but not in the BM or spleen (Figure 2A, 2B). Despite this effect, the YCP treatment did not change the percentage of macrophages in either the lung or liver (Figure 2C). These observations were further confirmed by immunofluorescence assays (Figure 2D). Surprisingly, YCP preferentially decreased the percentage of G-MDSCs (CD11b+Ly6G+Ly6Clow) even though both G-MDSCs and M-MDSCs (CD11b+Ly6G-Ly6Chigh) were increased in the septic mice (Figure 2E). These results suggest that YCP may protect the septic mice by decreasing the accumulation of MDSCs.
YCP inhibits the expansion of MDSCs in vitro via a STAT3-dependent pathway
The effect of YCP on mouse BM cells was first detected in vitro. Our results showed that low concentrations of YCP did not promote cytotoxicity in BM cells even after being co-cultured for up to 4 d (Figure 3A). Therefore, concentrations less than or equal to 100 μg/mL were chosen for the following in vitro experiments. However, YCP did decrease the number of BM cells (Figure 3B), which was attributed to BM cell apoptosis in vitro (Figure 3C, 3D).
To investigate the effect of YCP on the expansion of MDSCs, mouse BM cells were induced to differentiate into MDSCs. During the MDSC differentiation, varying concentrations of YCP were added to the culture medium, and a 1× PBS treatment was used as the control. We found that YCP significantly inhibited the expansion of MDSCs at d 2 and d 4 (Figure 4A, 4B). Notably, the YCP treatment significantly decreased G-MDSCs in a concentration-dependent manner, whereas M-MDSCs were decreased only when treated with high concentrations (Figure 4C, 4D), which is in agreement with the in vivo results.
Previous reports have shown that signal transducer and activator of transcription 3 (STAT3) is the main transcription factor that regulates the expansion of MDSCs under pathological conditions. Abnormal and persistent activation of STAT3 in myeloid progenitor cells promotes MDSC expansion37,38,39. Moreover, the expression of interferon regulatory factor-8 (IRF-8), which is downstream of STAT3, negatively regulates the accumulation of MDSCs in a STAT3-dependent manner40. STAT3 also regulates the expansion of MDSCs by inducing S100 calcium-binding protein A8 (S100A8) and S100A9 expression41,42. In our study, we found that YCP significantly reduced the phosphorylation of STAT3 (Figure 4E) and induced the expression of IRF-8 (Figure 4F). Additionally, our results showed that YCP repressed the expression of S100A8 and S100A9 (Figure 4G). Altogether, these data strongly suggest that YCP inhibits the expansion of MDSCs through a STAT3-dependent pathway.
YCP enhances the function of MDSCs partially through the NF-κB pathway
To investigate the function of MDSCs, we co-cultured BM-derived MDSCs with T cells. Surprisingly, we found that the YCP treatment enhanced the immunosuppressive function of both G-MDSCs and M-MDSCs toward T cells (Figure 5A). The levels of Arg-1, inducible nitric oxide synthase (iNOS) and ROS are essential for MDSC-mediated immunosuppression19,20,37,43,44 under certain pathological conditions. Thus, we explored whether YCP exerted its function through these molecules. The results demonstrated that YCP promoted the production of iNOS (Figure 5B, 5C) and Arg-1 (Figure 5D–5F), but not ROS (Figure 5G), in the BM-derived MDSCs. Our previous studies have shown that YCP activates the NF-κB pathway in macrophages16 and B cells17. In this study, our results also showed that YCP activated the NF-κB pathway in MDSCs (Figure 5H). Furthermore, we detected the expression levels of iNOS, Arg-1, P47phox and gp91phox in MDSCs isolated from the spleens of septic mice that survived 3 d after the CLP operation and were treated with or without YCP. In addition, we found that the YCP treatment promoted the expression of iNOS and Arg-1 but did not affect the expression of P47phox and gp91phox(Figure 5I), which were relative to the production of ROS, in vivo. In addition, these results were consistent with the in vitro results. Thus, our results indicate that YCP enhances the immunosuppressive function of MDSCs, at least partially, through the NF-κB pathway.
TLR4 acts as the YCP receptor on MDSCs
We have previously found that YCP binds to cells through an interaction with TLR2 and TLR415,16,17,18. To determine whether the effect of YCP on MDSCs is transmitted through one or both of these receptors, TLR2 and TLR4 knockout mice were used to obtain TLR2−/− or TLR4−/− BM cells. As expected, the absence of TLR4 in the TLR4−/− cells significantly influenced the effect of YCP on MDSC expansion (Figure 6A, 6B). Moreover, the level of IRF-8 in the TLR4−/− BM cells, compared with the normal cells, was significantly decreased after the YCP treatment (Figure 6C). Additionally, the effect of YCP on S100A8 (Figure 6D) and S100A9 (Figure 6E) expression was lost in the TLR4−/−, but not the TLR2−/−, BM cells. To evaluate the function of MDSCs, BM-derived MDSCs from normal, TLR2−/− and TLR4−/− mice were isolated and treated with 100 μg/mL YCP. The YCP-treated TLR4−/− MDSCs expressed lower levels of iNOS (Figure 6F) and Arg-1 (Figure 6G, 6H), compared with both normal and TLR2−/− MDSCs. Altogether, these results indicate that the TLR4 pathway is necessary for the YCP-mediated inhibition of MDSC expansion and functional enhancement.
Sepsis is frequently a fatal condition and is a major cause of death globally3,6,7,8. The current research direction is to search for effective therapeutic agents for the treatment of sepsis. In the present study, we found that the administration of the α-glucan YCP significantly alleviated multiple organ failure and increased the survival rates of septic mice. Furthermore, we found that YCP not only decreased the production of the pro-inflammatory cytokines IL-6 and TNFα but also regulated the differentiation and functions of MDSCs. The mechanistic study revealed that YCP inhibited the differentiation of MDSCs by blocking the STAT3 pathway and enhanced their functions by activating the NF-κB pathway.
MDSCs isolated from early stage septic mice are not sensitive to stimulation by LPS or IL-6 and produce low levels of Arg-1 and ROS and high levels of TNFα and IL-6 in vitro21,29. The adoptive transfer of MDSCs isolated from early stage septic mice into naive mice after CLP increased pro-inflammatory cytokine production and increased early mortality29. Thus, these types of cells may be deleterious in controlling sepsis in mice21,29. However, the treatment with YCP significantly altered the state of these MDSCs, simulating a phenotype that is more similar to that observed in late phase MDSCs, including increased iNOS and Arg-1 expression and decreased pro-inflammatory cytokine production in vivo. Thus, YCP may protect mice from the early sepsis response by increasing the immunosuppressive function of MDSCs. As the early sepsis response gradually evolves into a sustained immunosuppressed phase, MDSCs and other immunosuppressive cells are dramatically increased8,19,27,45 and are more sensitive to stimulation by LPS or IL-621. However, the excessive and persistently high proportion of immunosuppressive cells leads to death in late stage sepsis3,8,46. The YCP treatment decreased the percentage of MDSCs and inflammatory cell infiltration in the injured lung and liver and slightly protected the mice against late sepsis and death.
Previous studies have reported that β-glucans and α-glucans are biologically active when given through different routes of administration, including intraperitoneally, intravenously and orally11,12,13,14,47,48,49,50,51,52. In addition, there was a wide range of differences based on the doses of the different glucans used in these studies, and the variability may be due to the structure of the glucan and the routes of administration. To determine the optimal dose of YCP to use in vivo, we tested the effects of 10, 20, and 40 mg/kg YCP administered by intraperitoneal injections on the survival rate of septic mice (data not shown) and found that 20 mg/kg and 40 mg/kg YCP could significantly improve the survival rate. Notably, the effect of 40 mg/kg YCP is not better than that of 20 mg/kg. Hence, the dose of YCP used in this study is 20 mg/kg. Additionally, in this study, both intraperitoneal and intravenous administrations were used to deliver YCP to the septic mice. In addition, we found that YCP administered intraperitoneally improved the survival rate of mice almost equally to that administered intravenously.
STAT3 is arguably the main transcription factor that regulates the expansion of MDSCs37,38,39. Recent studies have suggested that STAT3 may enhance the expansion of MDSCs through the downregulation of IRF8 and the induction of S100A8/S100A940,41. S100A8/S100A9 complexes play an important role in inflammation41,42 and promote lethality in septic shock mouse models53,54. Moreover, IL-6, which is highly elevated in septic mice, can also activate the JAK-STAT3 pathway and promote the expansion of MDSCs37,55. Our results showed that YCP could directly inhibit the phosphorylation of STAT3, induce the expression of IRF8, repress the expression of S100A8 and S100A9 in vitro and decrease the level of IL-6 in septic mice in vivo. Therefore, YCP inhibited the expansion of MDSCs through a STAT3-dependent pathway. Interestingly, YCP only decreased the percentage of G-MDSCs but not that of M-MDSCs. Albeituni et al have reported that the phosphorylation of STAT3 was inhibited in G-MDSCs, but increased in M-MDSCs, following β-glucan stimulation50. The decreased STAT3 phosphorylation levels led to MDSC apoptosis50,56. In our study, YCP may also promote the apoptosis of G-MDSCs by inhibiting the STAT3 pathway. However, it is not clear why the accumulation of M-MDSCs was not affected.
We have previously demonstrated that YCP binds to cells via TLR2 and TLR415,16,17,18. In this study, our results showed that the absence of TLR4 affected the expansion and function of MDSCs. Although TLR4 is responsible for YCP's modulation of MDSCs, TLR4 is not the only YCP receptor. At high concentrations, the YCP treatment was also able to inhibit MDSC expansion in TLR4−/− BM cells and induce lower levels of iNOS and Arg-1 in TLR4−/− MDSCs. Recently, several groups have reported that β-glucan regulates the differentiation and function of MDSCs through dectin-1, which is a C-type lectin receptor50,51,52. Thus, YCP may activate MDSCs through other receptors that are not toll-like receptors.
In summary, the novel α-glucan YCP significantly protects mice against CLP-induced sepsis. Our findings suggest that the YCP treatment improves both the survival rates and disease symptoms in septic mice through the regulation of MDSC expansion and function. YCP may be a potential therapeutic agent for the treatment of sepsis.
This work was supported by a grant from the National Natural Science Foundation of China (Project No 91542113).